1.
J Natl Compr Canc Netw
; 11(10): 1187-91, 2013 Oct 01.
Article
in English
| MEDLINE
| ID: mdl-24142819
ABSTRACT
Imatinib mesylate represents a revolution in the management of patients with metastatic gastrointestinal stromal tumors (GISTs). More recently, postoperative imatinib has been shown to improve both disease-free and overall survivals in patients with a high risk of recurrence. This article presents a well-documented case of a patient with painful and reversible bone edema related to imatinib.